Regenerative medicine company Mesoblast says it will seek to engage with the powerful US regulator despite mixed results from its highly anticipated phase III trial into back pain using its rexlemestrocel-L drug.
Crucially, it wants to discuss with the Food and Drug Administration “if there is an accelerated path” for the drug as an opiate-sparing treatment for patients with degenerative disc disease.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
